105 related articles for article (PubMed ID: 38489872)
1. Novel players in the development of chemoresistance in ovarian cancer: ovarian cancer stem cells, non-coding RNA and nuclear receptors.
Alam S; Giri PK
Cancer Drug Resist; 2024; 7():6. PubMed ID: 38434767
[TBL] [Abstract][Full Text] [Related]
2. Ovarian cancer ascites confers platinum chemoresistance to ovarian cancer cells.
Carmi YK; Agbarya A; Khamaisi H; Farah R; Shechtman Y; Korobochka R; Gopas J; Mahajna J
Transl Oncol; 2024 Jun; 44():101939. PubMed ID: 38489872
[TBL] [Abstract][Full Text] [Related]
3. Flavonoids Restore Platinum Drug Sensitivity to Ovarian Carcinoma Cells in a Phospho-ERK1/2-Dependent Fashion.
Koren Carmi Y; Mahmoud H; Khamaisi H; Adawi R; Gopas J; Mahajna J
Int J Mol Sci; 2020 Sep; 21(18):. PubMed ID: 32906729
[TBL] [Abstract][Full Text] [Related]
4. Effect of combined inhibition of p110 alpha PI3K isoform and STAT3 pathway in ovarian cancer platinum-based resistance.
Le Naour A; Mevel R; Thibault B; Courtais E; Chantalat E; Delord JP; Couderc B; Guillermet-Guibert J; Martinez A
Oncotarget; 2018 Jun; 9(43):27220-27232. PubMed ID: 29930760
[TBL] [Abstract][Full Text] [Related]
5. Resveratrol Contrasts LPA-Induced Ovarian Cancer Cell Migration and Platinum Resistance by Rescuing Hedgehog-Mediated Autophagy.
Ferraresi A; Esposito A; Girone C; Vallino L; Salwa A; Ghezzi I; Thongchot S; Vidoni C; Dhanasekaran DN; Isidoro C
Cells; 2021 Nov; 10(11):. PubMed ID: 34831435
[No Abstract] [Full Text] [Related]
6. Secreted Soluble Factors from Tumor-Activated Mesenchymal Stromal Cells Confer Platinum Chemoresistance to Ovarian Cancer Cells.
Koren Carmi Y; Khamaisi H; Adawi R; Noyman E; Gopas J; Mahajna J
Int J Mol Sci; 2023 Apr; 24(9):. PubMed ID: 37175439
[TBL] [Abstract][Full Text] [Related]
7. Metabolite activation of tumorigenic signaling pathways in the tumor microenvironment.
Low V; Li Z; Blenis J
Sci Signal; 2022 Nov; 15(759):eabj4220. PubMed ID: 36346837
[TBL] [Abstract][Full Text] [Related]
8. Potential ovarian toxicity and infertility risk following targeted anti-cancer therapies.
Rosario R; Cui W; Anderson RA
Reprod Fertil; 2022 Jul; 3(3):R147-R162. PubMed ID: 35928672
[TBL] [Abstract][Full Text] [Related]
9. Combined Effects of 2-Methoxyestradiol (Hypoxia-Inducible Factor 1
Zhang Y; Chen H; Shen Y; Zhou X
J Immunol Res; 2022; 2022():6324326. PubMed ID: 35528614
[TBL] [Abstract][Full Text] [Related]
10. 2-Hydroxyestradiol Overcomes Mesenchymal Stem Cells-Mediated Platinum Chemoresistance in Ovarian Cancer Cells in an ERK-Independent Fashion.
Khamaisi H; Mahmoud H; Mahajna J
Molecules; 2022 Jan; 27(3):. PubMed ID: 35164068
[TBL] [Abstract][Full Text] [Related]
11. The JAK/STAT signaling pathway: from bench to clinic.
Hu X; Li J; Fu M; Zhao X; Wang W
Signal Transduct Target Ther; 2021 Nov; 6(1):402. PubMed ID: 34824210
[TBL] [Abstract][Full Text] [Related]
12. The implication of IL-6 in the invasiveness and chemoresistance of ovarian cancer cells. Systematic review of its potential role as a biomarker in ovarian cancer patients.
Szulc-Kielbik I; Kielbik M; Nowak M; Klink M
Biochim Biophys Acta Rev Cancer; 2021 Dec; 1876(2):188639. PubMed ID: 34695534
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
